Reza Mazhari, Ph.D.

Mazhari brings to Delphia more than 20 years of experience in drug discovery, clinical development and business development across diverse therapeutic areas including oncology. 

Prior to joining Delphia, Dr. Mazhari was chief business officer at Triana Biomedicines, where he led a discovery partnership with Pfizer in 2024. Prior to joining Triana, he was the head of search and evaluations for oncology at Novartis, where he led numerous successful in-licensing deals that contributed to the early-stage oncology pipeline and expanded the portfolio of enabling technologies, while also leading out-licensing efforts for early-stage programs. Previously, Dr. Mazhari was the vice president of translational medicine and head of business development and licensing at Rexahn Pharmaceuticals. At Cerecor, he was vice president of drug discovery and early development, and led business development. Dr. Mazhari was the co-founder and vice president of research and pharmacology at Cardioxyl Pharmaceuticals, which was acquired by Bristol-Myers Squibb in 2015. He began his career as a faculty member at the School of Medicine in The Johns Hopkins University.

Dr. Mazhari holds a Ph.D. in bioengineering from University of California at San Diego and a postdoctoral research fellowship in cardiovascular medicine from The Johns Hopkins School of Medicine.